According to reports in the diabetes news, diabetes drug company AtheroGenics Inc. have claimed that their experimental diabetic drug AGI-1067 has passed main goals in clinical trials . The drug has apparently helped to treat people with type 2 diabetes by reducing blood glucose levels.
The trial, called ANDES, is investigating two different dosages of the drug, 75mg and 150mg. The company will now continue to analyse the trial data, and conduct a further additional trial in line with Food and Drug Administration development plan.
Industry reports indicate that AtheroGenics are in discussion with various potential partners, but the Chief Executive of the company warned that he could not give further details until anything was confirmed.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…